Aprepitant Regimen Reduced CINV in Post-Transplant Myeloma

Share this content:
Aprepitant Regimen Reduced CINV in Post-Transplant Myeloma
Aprepitant Regimen Reduced CINV in Post-Transplant Myeloma
The addition of the NK-1 antagonist aprepitant to granisetron and dexamethasone reduced nausea and vomiting among patients with myeloma who underwent high-dose chemotherapy and autologous stem cell transplantation, according to results of a randomized, phase 3 trial.
READ FULL ARTICLE From HealIO
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »